Acasunlimab, an Fc-inert PD-L1×4-1BB bispecific antibody, combined with PD-1 blockade potentiates antitumor immunity via complementary immune modulatory effects.

J Immunother Cancer · 2025 · PMC11987116 · PMID 40216443

Europe PMC DOI

hedged sentence

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendp=0.06so close (0.05 < p ≤ 0.1)

While anti-mPD-L1×m4-1BB showed a trend of increased PFS (p=0.06 vs control), PFS was significantly extended by the combination (p<0.001 vs control).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.